JP2020505342A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505342A5
JP2020505342A5 JP2019537357A JP2019537357A JP2020505342A5 JP 2020505342 A5 JP2020505342 A5 JP 2020505342A5 JP 2019537357 A JP2019537357 A JP 2019537357A JP 2019537357 A JP2019537357 A JP 2019537357A JP 2020505342 A5 JP2020505342 A5 JP 2020505342A5
Authority
JP
Japan
Prior art keywords
agent
antibody
cells
nrn1
sema7a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019537357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505342A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/014008 external-priority patent/WO2018186924A1/en
Publication of JP2020505342A publication Critical patent/JP2020505342A/ja
Publication of JP2020505342A5 publication Critical patent/JP2020505342A5/ja
Priority to JP2022139514A priority Critical patent/JP2022184862A/ja
Pending legal-status Critical Current

Links

JP2019537357A 2017-01-17 2018-01-17 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 Pending JP2020505342A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022139514A JP2022184862A (ja) 2017-01-17 2022-09-01 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447199P 2017-01-17 2017-01-17
US62/447,199 2017-01-17
PCT/US2018/014008 WO2018186924A1 (en) 2017-01-17 2018-01-17 Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022139514A Division JP2022184862A (ja) 2017-01-17 2022-09-01 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞

Publications (2)

Publication Number Publication Date
JP2020505342A JP2020505342A (ja) 2020-02-20
JP2020505342A5 true JP2020505342A5 (enExample) 2021-03-04

Family

ID=63712313

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537357A Pending JP2020505342A (ja) 2017-01-17 2018-01-17 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞
JP2022139514A Pending JP2022184862A (ja) 2017-01-17 2022-09-01 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022139514A Pending JP2022184862A (ja) 2017-01-17 2022-09-01 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞

Country Status (6)

Country Link
US (3) US11566077B2 (enExample)
EP (1) EP3570887A4 (enExample)
JP (2) JP2020505342A (enExample)
CN (1) CN110740748A (enExample)
CA (1) CA3049445A1 (enExample)
WO (1) WO2018186924A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc. anticorpos anti-cd137 e métodos de uso dos mesmos
WO2020109627A1 (en) * 2018-11-30 2020-06-04 Institut Gustave Roussy Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer
WO2020146772A1 (en) * 2019-01-11 2020-07-16 The Johns Hopkins University Neuritin regulation of t cell anergy and t regulatory cell function
CN109913414A (zh) * 2019-03-21 2019-06-21 吉林省银丰生物工程技术有限公司 肝癌afp特异性人工抗原递呈细胞诱导试剂盒
US20210130438A1 (en) * 2019-10-28 2021-05-06 The Broad Institute, Inc. Pan-cancer t cell exhaustion genes
EP4090371A4 (en) * 2020-01-14 2024-04-03 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY RE-ROUTING ENDOGENOUS DEUBIQUITINASES
US20230226118A1 (en) * 2020-03-17 2023-07-20 Ohio State Innovation Foundation Designer extracellular vesicles for treating excitotoxicity
JP7565381B2 (ja) * 2020-05-15 2024-10-10 博迪賀康（北京）生物技術有限公司 Ｔ細胞、その調製方法及び使用
CN111781358A (zh) * 2020-07-13 2020-10-16 张瑜 Xab2蛋白作为卵巢癌预后和/或预测铂类耐药标志物
CN112481375B (zh) * 2020-08-27 2024-02-20 江苏大学 一种胃癌标志物及其应用
CN114350616A (zh) * 2022-01-24 2022-04-15 深圳市先康达生命科学有限公司 一种免疫细胞及其制备方法和应用
CN114814231B (zh) * 2022-03-08 2024-08-27 上海交通大学医学院附属瑞金医院 维甲酸诱导基因i在癌症治疗中的应用
CN114561389A (zh) * 2022-03-15 2022-05-31 南通市肿瘤医院 Vrk1表达抑制剂及其应用
US20230313306A1 (en) * 2022-03-21 2023-10-05 Feng Xue Methods of Diagnosis of Alzheimer's Disease by Monitoring STING Signaling Activation
CN115631857B (zh) * 2022-04-01 2023-06-23 洛兮医疗科技(杭州)有限公司 甲状腺癌cd8+t细胞免疫相关基因预后预测模型
CN114720691B (zh) * 2022-05-10 2022-12-09 深圳粒影生物科技有限公司 一种检测生物标志物的试剂盒及其制备方法和应用
CN115449548A (zh) * 2022-09-20 2022-12-09 南京鼓楼医院 Stac2卵丘细胞在评估卵母细胞受精能力中的应用
CN116904309B (zh) * 2023-05-26 2026-04-03 西安天隆科技有限公司 能平衡样本管接收部传热差异的模块、方法及pcr装置
CN117192127B (zh) * 2023-08-18 2024-06-14 肇庆医学高等专科学校 一种hcc治疗靶点的发现方法
CN117590001A (zh) * 2023-11-22 2024-02-23 厦门大学 外泌体tmem176b在制备诊断肿瘤的药物中的用途
CN119120385B (zh) * 2024-11-14 2025-03-14 四川大学华西医院 一种具有长效抑瘤效果的嵌合抗原受体t细胞及其制备方法和用途
CN121046325B (zh) * 2025-11-03 2026-03-17 杭州克斯珀基因技术有限公司 增强肿瘤微环境适应性的cep20敲除型til的制备方法及应用
CN121114292B (zh) * 2025-11-13 2026-01-23 合肥谱佳医学检验实验室有限公司 体外定量检测人血清中四种神经酰胺化合物的检测试剂盒

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA877772B (en) 1986-10-23 1988-04-20 Amoco Corporation Target and background capture methods and apparatus for affinity assays
US20070072209A1 (en) 2005-07-07 2007-03-29 Ashlee Moses Methods of treatment and diagnosis of Kaposi's sarcoma (KS) and KS related diseases
WO2008133641A2 (en) * 2006-10-11 2008-11-06 Curagen Corporation Antibodies directed to gpnmb and uses thereof
US8637084B2 (en) * 2009-07-14 2014-01-28 Asahi Kasei Medical Co., Ltd. Treatment method for epithelial cancerous organism
US9163087B2 (en) * 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
JP2012025694A (ja) * 2010-07-23 2012-02-09 Asahi Kasei Kuraray Medical Co Ltd 癌治療剤
NZ729044A (en) * 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
US9297813B2 (en) 2010-11-11 2016-03-29 Agency For Science, Technology And Research Targeting metabolic enzymes in human cancer
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
ES2935257T3 (es) * 2013-03-15 2023-03-03 Univ Chicago Métodos y composiciones relacionadas con la actividad de las células T
US10899840B2 (en) * 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
AU2015330898B2 (en) * 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
AU2016205215B2 (en) * 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
CN108495651A (zh) * 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
CA3026182A1 (en) 2016-06-03 2017-12-07 Steven Greenberg Klrg1 signaling therapy

Similar Documents

Publication Publication Date Title
Sharma et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
CN113286811B (zh) 改善过继性细胞疗法的效力和安全性
CN110475571B (zh) 细胞免疫疗法前细胞毒性预调理的替代
Prieto et al. Immunological landscape and immunotherapy of hepatocellular carcinoma
Aris et al. Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment
JP2025013518A (ja) Ｃａｒの抗腫瘍活性のための毒性管理
Patel et al. Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
Wang et al. What happens to the immune microenvironment after PD-1 inhibitor therapy?
Cabo et al. Trial watch: immunostimulatory monoclonal antibodies for oncological indications
Hebb et al. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression
JP7447011B2 (ja) エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用
CN108289912A (zh) 具有提高的免疫力或免疫抑制性细胞因子抗性的免疫细胞及其用途
JP2017507936A5 (enExample)
JP2015508816A5 (enExample)
Niedbała et al. Glioblastoma: pitfalls and opportunities of immunotherapeutic combinations
JP2022523804A (ja) がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤
Zhang et al. Current advances and challenges in CAR-T therapy for hematological and solid tumors
CN112351795A (zh) 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法
US20230096897A1 (en) Lymphocyte Population and Methods for Producing Same
Shah et al. Multiple myeloma, targeting B-cell maturation antigen with chimeric antigen receptor T-cells
Rossari et al. Treatment options for advanced hepatocellular carcinoma: the potential of biologics
Mandalà et al. Rational combination of cancer immunotherapy in melanoma
Akabane et al. Advancing adjuvant immunotherapy in hepatocellular carcinoma: a comprehensive review
Liu et al. Endogenous immune recruitment in glioblastoma CAR T therapy: Cytokine, myeloid, and chemokine circuitry
Bose Immune checkpoint blockers and ovarian cancer